Dr. Christopher A. Klebanoff

Dr. Christopher A. Klebanoff, MD, is a medical oncologist and translational researcher specializing in early drug development for breast cancer. He is a member of the Center for Cell Engineering and the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, where he combines laboratory research with clinical trial work to advance novel cancer therapies. His scientific expertise spans cellular therapy and genetic engineering, immune-stimulating antibodies and cytokines, and cancer vaccines. Driven by a deep personal understanding of cancer's impact, having experienced its effects within his own family, Dr. Klebanoff brings both scientific rigor and genuine empathy to his clinical practice.

Dr. Klebanoff's research centers on harnessing the power of the immune system to fight breast cancer, a disease he views as one where immunotherapy's full potential is still being uncovered. Working across both laboratory and clinical settings, he develops therapies designed to be more effective and less toxic than existing options. His participation in clinical trials through the Parker Institute and Center for Cell Engineering reflects his commitment to translating promising scientific findings into meaningful treatment advances for patients with breast cancer.

Patient communication and collaboration are central to how Dr. Klebanoff practices medicine. He is committed to ensuring that patients and their families fully understand their diagnosis, the available treatment options, and the evidence behind each approach, presenting complex medical information in clear and accessible terms. He prioritizes open lines of communication between patients and their care teams throughout treatment and follow-up, so that no patient feels isolated or alone. His goal is to provide individualized care that addresses both the physical and emotional dimensions of a cancer diagnosis.